ClinicalTrials.gg
CompletedNCT02275845Medico-GDMUpdated Oct 9, 2026

Medico-GDM Trial - Metformine to Prevent Gestational Diabetes Mellitus

A Phase 3 interventional study of Metformin and control diet in Gestational Diabetes Mellitus, sponsored by Maasstad Hospital. Completed at 1 site in Netherlands. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Maasstad Hospital · Phase 3, Interventional, and Prevention

How we know

Updated Oct 9, 2026Now CompletedStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 39 studies testing metformin in Diabetes, Gestational — 4 open to participants now, 5 under way, none of them phase 3. Metformin · Diabetes, Gestational.

Planned enrollment
4th of 39
400 · median 112
Started
2014
with 1 other
Phase 3
12 of 39
none open now
Registered
20th of 39
by date

Among the 39 studies testing metformin in Diabetes, Gestational, this one is the 4th largest by planned enrollment, is one of 2 that started in 2014, is one of 12 in phase 3, and was the 20th registered.

Diabetes, Gestational

878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.

Browse Diabetes, Gestational studies →

Open to participants now

4 of the 39 studies testing metformin in Diabetes, Gestational are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 40 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing metformin in Diabetes, Gestational, or all of them as a file.
02

Study summary

Metformin vs Control to prevent gestational diabetes mellitus (GDM) in women with a high risk for GDM, an open label randomized controlled trial' The Medico-GDM trial

Read the detailed description

Rationale: GDM is a frequent pregnancy complication1 and associated with complications for mother and child.2 At present, the drug of choice for treatment of GDM is Insulin.3 In the last years several studies documented the use of oral blood glucose lowering medication in GDM. Metformin is an accepted alternative for insulin, with comparable glycemic control and neonatal outcomes.4 In studies with women with polycystic ovarian syndrome (PCOS) who received Metformin during pregnancy, the incidence of GDM is less compared to pregnant women with PCOS without Metformin. These studies were however small and there was no adequate control group.5 Our aim is to study the effect of Metformin on the incidence of GDM in women with a high risk for GDM.

Objective: the primary objective is to compare metformin versus no intervention for incidence of GDM in women with a high risk for GDM. The main secondary objective is pregnancy outcome with Metformin, neonatal outcomes and neonatal complications.

Study design: 2 years open label randomized controlled trial, comparing metformin versus control group.

Study population: pregnant women with a high risk of GDM between 18 and 40 years old in the first trimester of pregnancy.

Intervention: the first group receives Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg. The second group receives no intervention. All the subjects are receiving a diet which contains a 2000 calories/day diet, with an adequate distribution of carbohydrates during the day.

Main study parameters/endpoints: the main study parameter is the difference in incidence of GDM between the two groups.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: the subjects will visit our centre for the first time between 12 and 14 weeks of pregnancy, then blood samples will be collected. Further on they will visit our centre at 24 weeks to perform an oral glucose tolerance test (OGTT). Women with GDM in history will perform an OGTT at 16 weeks for the first time. If the OGTT is borderline normal, it will repeated every 4 weeks. This is according to current Dutch guidelines3, without any extra discomfort for study participants. The subjects will visit their own gynaecologist or obstretican for their regular pregnancy controls. Metformin is not officially registered for use in pregnancy. Long term effects for the unborn child are not known. However, previous studies did not found neonatal and pregnancy related complications.

03

Conditions studied

  • Gestational Diabetes Mellitus

Browse trials for

Keywords

  • metformin
  • prevention
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

a subject must meet all of the following criteria:

  • high risk (according to ductch national criteria) for gestational diabetes
  • aged between 18 and 40 years
  • gestational age between 8 and 12 weeks
  • and able to communicate and read in Dutch.

Exclusion criteria

Exclusion Criteria:

A potential subject who meets any of the following criteria will be excluded from participation in this study:

  • no singleton pregnancy judged by ultrasonography
  • diagnosis of diabetes mellitus before the current pregnancy-
  • high fasting glucose at first trimester (> 5.3 mmol/l)
  • cardiac insufficiency-\
  • renal insufficiency ( \< 60)
  • liver disease
  • use of medication other than Paracetamol or vitamins and incompetent women.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    intervention

    Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg. All the subjects are receiving a diet which contains a 2000 calories/day diet, with an adequate distribution of carbohydrates during the day.

    Drug: Metformin · Other: control diet

  • Active comparator
    control diet

    a diet which contains a 2000 calories/day diet, with an adequate distribution of carbohydrates during the day.

    Other: control diet

Interventions

  • Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg (from 14 weeks pregnancy untill delivery)

  • Othercontrol diet

    2000 calories/day diet, with an adequate distribution of carbohydrates during the day

06

What researchers measure

Primary outcomes

  1. incidence of gestational diabetes mellitus in both groups

    Time frame: from 14 weeks pregnancy untill delivery

Secondary outcomes

  1. Maternal outcomes

    Maternal: pregnancy induced hypertension (yes vs no: systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg), weight gain during pregnancy (kg), abnormal glucose daily curve after pregnancy (yes vs no: measurement of blood glucose concentration seven times daily).), insulin therapy required.

    Time frame: from 14 weeks pregnancy untill delivery

  2. Neonatal outcomes

    head circumference (cm), birth weight (g) and height (cm), pH of umbilical-cord. Neonatal complications: serious neonatal complications (including: severe birth defects, stillbirth, birth trauma, respiratory distress, admission to neonatal intensive care unit, low 5-minutes Apgar score (\< 7) and premature birth (\< 37 weeks of gestation)), neonatal hypoglycaemia that requires therapy, need for phototherapy, small for gestational age (birth weight \< 2 SD units), birth weight \> 90th percentile, birth weight \< 10th percentile.

    Time frame: from 14 weeks pregnancy untill delivery

07

Study locations

1 site
  • Maasstad Ziekenhuis
    Rotterdam, Netherlands
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2014 to primary completion in Mar 2017, 28 months.

Of 14 phase 3 interventional studies under Diabetes, Gestational, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's 28 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: start Sep 2014 → Oct 2014, primary completion Sep 2016 → Mar 2017 and completion Sep 2017 → Mar 2017.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2014
First posted
Oct 27, 2014
StartActual
Oct 8, 2014was Sep 2014
Primary completionActual
Mar 3, 2017was Sep 2016
CompletionActual
Mar 3, 2017was Sep 2017
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 9, 2026
Start date
Sep 2014→Oct 8, 2014 (actual)
Oct 9, 2026
Primary completion
Sep 2016→Mar 3, 2017 (actual)
Oct 9, 2026
Study completion
Sep 2017→Mar 3, 2017 (actual)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Status unknown→Completed
    Start date Sep 2014→Oct 8, 2014 (now actual)
    Primary completion Sep 2016→Mar 3, 2017 (now actual)
    Study completion Sep 2017→Mar 3, 2017 (now actual)
    + 4 other changes: index terms, identifiers, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT02275845
Lead sponsor
Maasstad Hospital
Responsible party
Wetenschapsbureau (dr. J. van der Linden, Maasstad Hospital) — Principal investigator
First posted
Oct 27, 2014
Start date
Oct 8, 2014
Primary completion
Mar 3, 2017
Completion
Mar 3, 2017
Last update
Oct 9, 2026

Study contacts

Joke van der Linden, dr.
principal investigator · Maasstad Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion